𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation

✍ Scribed by Masayoshi Yamaguchi; M. Neale Weitzmann


Publisher
Springer
Year
2011
Tongue
English
Weight
469 KB
Volume
355
Category
Article
ISSN
0300-8177

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Maslinic acid suppresses osteoclastogene
✍ Chenghai Li; Zhengfeng Yang; Zhenxi Li; Yu Ma; Lipeng Zhang; Chunbing Zheng; Wen 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 714 KB

## Abstract Activation of NF‐κB and MAPK/activator protein 1 (AP‐1) signaling pathways by receptor activator NF‐κB ligand (RANKL) is essential for osteoclast activity. Targeting NF‐κB and MAPK/AP‐1 signaling to modulate osteoclast activity has been a promising strategy for osteoclast‐related diseas

Simvastatin, 3-hydroxy-3-methylglutaryl
✍ Kwang Seok Ahn; Gautam Sethi; Madan M. Chaturvedi; Bharat B. Aggarwal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 631 KB

## Abstract Simvastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase, is a cholesterol‐lowering drug that may play a role in bone metabolism through a mechanism that is not fully understood. Recently, receptor activator of NF‐κB ligand (RANKL), a member of the TNF superfamily, h

Caffeic acid phenethyl ester, an active
✍ Estabelle S.M. Ang; Nathan J. Pavlos; Lee Y. Chai; Ming Qi; Tak S. Cheng; James 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

## Abstract Receptor activator NF‐κB ligand (RANKL)‐activated signaling is essential for osteoclast differentiation, activation and survival. Caffeic acid phenethyl ester (CAPE), a natural NF‐κB inhibitor from honeybee propolis has been shown to have anti‐tumor and anti‐inflammatory properties. In

The antirheumatic drug leflunomide inhib
✍ Makoto Urushibara; Hiroshi Takayanagi; Takako Koga; Sunhwa Kim; Miho Isobe; Yasu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB 👁 2 views

## Abstract ## Objective Suppression of bone destruction is required as part of an effective therapeutic strategy for autoimmune arthritis. Although numerous antirheumatic drugs are in clinical use, little is known about whether they inhibit bone destruction by acting on activated T cells or other